Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma
暂无分享,去创建一个
[1] M. Stratton,et al. The cancer genome , 2009, Nature.
[2] J. Flickinger,et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era , 2010, Journal of Neuro-Oncology.
[3] Maria Werner-Wasik,et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. , 2004, International journal of radiation oncology, biology, physics.
[4] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[5] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[6] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[7] Benedick A Fraass,et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Olson,et al. The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine , 2002, Neurosurgery.
[9] M. Mehta,et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. , 2005, International journal of radiation oncology, biology, physics.
[10] S. Sasaki,et al. Treatment Outcome of Elderly Patients With Glioblastoma who Received Combination Therapy , 2012, American journal of clinical oncology.
[11] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[12] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[13] E S Newlands,et al. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. , 1997, Cancer treatment reviews.
[14] C. Kennard,et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.
[15] D. Scudiero,et al. Sensitivity of human cell strains having different abilities to repair O6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. , 1984, Cancer research.
[16] M. Berger,et al. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. , 2001, Cancer research.
[17] W. Curran,et al. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. , 2009, International journal of radiation oncology, biology, physics.
[18] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] G. Reifenberger,et al. NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Carter,et al. 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. , 1972, European journal of cancer.
[21] J. Hickman,et al. DNA cross-linking and cytotoxicity in normal and transformed human cells treated in vitro with 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d] -1,2,3,5-tetrazin-4(3H)-one. , 1984, Cancer research.
[22] E. Newlands,et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.
[23] T. Cascino,et al. Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] B. Scheithauer,et al. The New WHO Classification of Brain Tumours , 1993, Brain pathology.
[25] E. Newlands,et al. In vitro evaluation of temozolomide combined with X-irradiation , 1997, Anti-cancer drugs.
[26] W. J. German,et al. Glioblastoma multiforme. , 2014, Journal of Insurance Medicine.
[27] T. Kinsella,et al. Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study. , 1996, International journal of radiation oncology, biology, physics.
[28] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[29] R. Stupp,et al. Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Godlee,et al. HOSPITAL FOR EPILEPSY AND PARALYSIS, REGENT'S PARK.: EXCISION OF A TUMOUR FROM THE BRAIN , 1884 .
[31] M. Tisdale. Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones. , 1987, Biochemical pharmacology.
[32] E. Newlands,et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.
[33] E. Newlands,et al. Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. , 1996, British Journal of Cancer.
[34] J. Heimans,et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays. , 2000, International journal of radiation oncology, biology, physics.
[35] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[36] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[37] M. Bernstein,et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. , 1998, International journal of radiation oncology, biology, physics.
[38] Shiao Y. Woo,et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. , 2007, International journal of radiation oncology, biology, physics.
[39] S P Langdon,et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. , 1987, Cancer research.
[40] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Hockaday,et al. Letter: Ectopic production of calcitonin. , 1973, Lancet.
[42] E. Gehan,et al. Evaluation of mithramycin in the treatment of anaplastic gliomas. , 1976, Journal of neurosurgery.
[43] J. French,et al. Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. , 1952, Journal of neurosurgery.
[44] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[45] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[46] J. Martin,et al. A study of 211 patients with verified glioblastoma multiforme. , 1948, Transactions of the American Neurological Association.